Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nexstim OyjFRA:5NX +6.07%69 Debt-to-EBITDA is 6.49 as of Jun. 2026. GuruFocus rates FRA:5NX with a GF Score™ of 69/100 and a GF Value™ of €9.65 (Fairly Valued). The stock has 5 warning signs investors should review. Among 471 Medical Devices & Instruments companies, Nexstim Oyj ranks worse than 57.96% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Nexstim Oyj's Debt-to-EBITDA or its related term are showing as below:
FRA:5NX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.68 Med: -0.65 Max: 11.76
Current: 1.98
During the past 13 years, the highest Debt-to-EBITDA Ratio of Nexstim Oyj was 11.76. The lowest was -8.68. And the median was -0.65.
FRA:5NX's Debt-to-EBITDA is ranked worse than 57.96% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs FRA:5NX: 1.98
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Nexstim Oyj Debt-to-EBITDA Related Terms
Nexstim Oyj Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Nexstim Oyj's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5NX vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Nexstim Oyj's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexstim Oyj Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nexstim Oyj's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nexstim Oyj's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Nexstim Oyj (FRA:5NX) has a Debt-to-EBITDA of 6.49 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nexstim Oyj. According to the industry distribution chart, Nexstim Oyj ranks #273 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 58%.
Is Nexstim Oyj's Debt-to-EBITDA too high?
Nexstim Oyj's current Debt-to-EBITDA is 6.49. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.63. Nexstim Oyj's value of 6.49 is 298.2% above this industry median. Based on the distribution chart, Nexstim Oyj ranks #273 out of 471 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nexstim Oyj has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nexstim Oyj's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nexstim Oyj ranks #273 out of 471 companies for Debt-to-EBITDA. This places Nexstim Oyj in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Nexstim Oyj's value of 6.49 is 298.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nexstim Oyj's current Debt-to-EBITDA of 6.49 is 298.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nexstim Oyj. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nexstim Oyj's current Debt-to-EBITDA is 6.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexstim Oyj stock overvalued right now?
Based on GuruFocus' analysis, Nexstim Oyj (FRA:5NX) is currently considered Fairly Valued. The stock's GF Value™ is €9.65, compared to a current price of €9.78 — trading 1.3% above its estimated fair value. The current Debt-to-EBITDA is 6.49 and 298.2% above the Medical Devices & Instruments industry median of 1.63. Nexstim Oyj's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Nexstim Oyj (FRA:5NX), the current Debt-to-EBITDA is 6.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nexstim Oyj (FRA:5NX) Overvalued in 2026?
Based on GuruFocus' analysis, Nexstim Oyj stock appears to be overvalued.
The current stock price of €9.78 is trading 1.3% above its estimated GF Value™ of €9.65.
GuruFocus considers Nexstim Oyj to be Fairly Valued.
Key valuation signals for FRA:5NX:
Debt-to-EBITDA: 6.49
GF Value™: €9.65 vs. price of €9.78 (1.3% above fair value)
Industry Position: 298.2% above the Medical Devices & Instruments median (#273 of 471)
No single metric tells the full story. See the FRA:5NX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nexstim Oyj is a Finnish medical technology company. It has developed a non-invasive brain-stimulation technology for navigated transcranial magnetic stimulation (nTMS), with sophisticated 3D navigation that provides accurate, personalized targeting of TMS to specific brain areas. The company's diagnostic business focuses on commercializing the NBS System 6, an FDA-cleared, CE-marked navigated TMS system for pre-surgical mapping of the brain's speech and motor cortices. Its therapy business sells the NBS System 6 for the treatment of depressive disorder in the United States, and for the treatment of depression, chronic neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb, in Europe. Geographically, the firm generates maximum revenue from North America.
69GF Score
Get the complete analysis for FRA:5NX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5NX has been successfully added to your 
